nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—Corticosteroid Hormone Receptor Agonists—Methylprednisolone—multiple sclerosis	0.0647	0.178	CiPCiCtD
Fluocinolone Acetonide—Corticosteroid Hormone Receptor Agonists—Betamethasone—multiple sclerosis	0.0623	0.172	CiPCiCtD
Fluocinolone Acetonide—Corticosteroid Hormone Receptor Agonists—Dexamethasone—multiple sclerosis	0.0623	0.172	CiPCiCtD
Fluocinolone Acetonide—Corticosteroid Hormone Receptor Agonists—Triamcinolone—multiple sclerosis	0.0602	0.166	CiPCiCtD
Fluocinolone Acetonide—Corticosteroid Hormone Receptor Agonists—Prednisolone—multiple sclerosis	0.0583	0.161	CiPCiCtD
Fluocinolone Acetonide—Corticosteroid Hormone Receptor Agonists—Prednisone—multiple sclerosis	0.055	0.152	CiPCiCtD
Fluocinolone Acetonide—Methylprednisolone—multiple sclerosis	0.0539	0.207	CrCtD
Fluocinolone Acetonide—Dexamethasone—multiple sclerosis	0.0531	0.204	CrCtD
Fluocinolone Acetonide—Betamethasone—multiple sclerosis	0.0531	0.204	CrCtD
Fluocinolone Acetonide—Triamcinolone—multiple sclerosis	0.0518	0.199	CrCtD
Fluocinolone Acetonide—Prednisolone—multiple sclerosis	0.048	0.185	CrCtD
Fluocinolone Acetonide—SERPINA6—Triamcinolone—multiple sclerosis	0.0324	0.231	CbGbCtD
Fluocinolone Acetonide—SERPINA6—Prednisolone—multiple sclerosis	0.0274	0.195	CbGbCtD
Fluocinolone Acetonide—NR3C1—Methylprednisolone—multiple sclerosis	0.02	0.142	CbGbCtD
Fluocinolone Acetonide—NR3C1—Triamcinolone—multiple sclerosis	0.0151	0.108	CbGbCtD
Fluocinolone Acetonide—NR3C1—Betamethasone—multiple sclerosis	0.013	0.0925	CbGbCtD
Fluocinolone Acetonide—NR3C1—Prednisolone—multiple sclerosis	0.0128	0.0913	CbGbCtD
Fluocinolone Acetonide—NR3C1—Prednisone—multiple sclerosis	0.0121	0.0862	CbGbCtD
Fluocinolone Acetonide—NR3C1—Dexamethasone—multiple sclerosis	0.00755	0.0538	CbGbCtD
Fluocinolone Acetonide—Fluticasone furoate—Betamethasone—multiple sclerosis	0.00176	0.00915	CrCrCtD
Fluocinolone Acetonide—Fluticasone furoate—Dexamethasone—multiple sclerosis	0.00176	0.00915	CrCrCtD
Fluocinolone Acetonide—Fluticasone furoate—Triamcinolone—multiple sclerosis	0.00171	0.00894	CrCrCtD
Fluocinolone Acetonide—Flurandrenolide—Methylprednisolone—multiple sclerosis	0.00166	0.00864	CrCrCtD
Fluocinolone Acetonide—Flurandrenolide—Dexamethasone—multiple sclerosis	0.00163	0.0085	CrCrCtD
Fluocinolone Acetonide—Flurandrenolide—Betamethasone—multiple sclerosis	0.00163	0.0085	CrCrCtD
Fluocinolone Acetonide—Flumethasone Pivalate—Methylprednisolone—multiple sclerosis	0.0016	0.00835	CrCrCtD
Fluocinolone Acetonide—Flumethasone Pivalate—Dexamethasone—multiple sclerosis	0.00158	0.00822	CrCrCtD
Fluocinolone Acetonide—Flumethasone Pivalate—Betamethasone—multiple sclerosis	0.00158	0.00822	CrCrCtD
Fluocinolone Acetonide—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.00155	0.00808	CrCrCtD
Fluocinolone Acetonide—Halobetasol Propionate—Methylprednisolone—multiple sclerosis	0.00155	0.00808	CrCrCtD
Fluocinolone Acetonide—Difluprednate—Methylprednisolone—multiple sclerosis	0.00155	0.00808	CrCrCtD
Fluocinolone Acetonide—Flumethasone Pivalate—Triamcinolone—multiple sclerosis	0.00154	0.00803	CrCrCtD
Fluocinolone Acetonide—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.00153	0.00796	CrCrCtD
Fluocinolone Acetonide—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.00153	0.00796	CrCrCtD
Fluocinolone Acetonide—Difluprednate—Betamethasone—multiple sclerosis	0.00153	0.00796	CrCrCtD
Fluocinolone Acetonide—Halobetasol Propionate—Betamethasone—multiple sclerosis	0.00153	0.00796	CrCrCtD
Fluocinolone Acetonide—Halobetasol Propionate—Dexamethasone—multiple sclerosis	0.00153	0.00796	CrCrCtD
Fluocinolone Acetonide—Difluprednate—Dexamethasone—multiple sclerosis	0.00153	0.00796	CrCrCtD
Fluocinolone Acetonide—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.00149	0.00777	CrCrCtD
Fluocinolone Acetonide—Halobetasol Propionate—Triamcinolone—multiple sclerosis	0.00149	0.00777	CrCrCtD
Fluocinolone Acetonide—Difluprednate—Triamcinolone—multiple sclerosis	0.00149	0.00777	CrCrCtD
Fluocinolone Acetonide—Flurandrenolide—Prednisolone—multiple sclerosis	0.00148	0.0077	CrCrCtD
Fluocinolone Acetonide—Fluocinonide—Methylprednisolone—multiple sclerosis	0.00146	0.0076	CrCrCtD
Fluocinolone Acetonide—Clocortolone—Methylprednisolone—multiple sclerosis	0.00146	0.0076	CrCrCtD
Fluocinolone Acetonide—Beclomethasone—Betamethasone—multiple sclerosis	0.00144	0.00748	CrCrCtD
Fluocinolone Acetonide—Beclomethasone—Dexamethasone—multiple sclerosis	0.00144	0.00748	CrCrCtD
Fluocinolone Acetonide—Clocortolone—Dexamethasone—multiple sclerosis	0.00144	0.00748	CrCrCtD
Fluocinolone Acetonide—Fluocinonide—Betamethasone—multiple sclerosis	0.00144	0.00748	CrCrCtD
Fluocinolone Acetonide—Fluocinonide—Dexamethasone—multiple sclerosis	0.00144	0.00748	CrCrCtD
Fluocinolone Acetonide—Clocortolone—Betamethasone—multiple sclerosis	0.00144	0.00748	CrCrCtD
Fluocinolone Acetonide—Fluocortolone—Methylprednisolone—multiple sclerosis	0.00142	0.00738	CrCrCtD
Fluocinolone Acetonide—Fluocinonide—Triamcinolone—multiple sclerosis	0.0014	0.00731	CrCrCtD
Fluocinolone Acetonide—Beclomethasone—Triamcinolone—multiple sclerosis	0.0014	0.00731	CrCrCtD
Fluocinolone Acetonide—Clocortolone—Triamcinolone—multiple sclerosis	0.0014	0.00731	CrCrCtD
Fluocinolone Acetonide—Fluocortolone—Dexamethasone—multiple sclerosis	0.00139	0.00727	CrCrCtD
Fluocinolone Acetonide—Fluocortolone—Betamethasone—multiple sclerosis	0.00139	0.00727	CrCrCtD
Fluocinolone Acetonide—Alclometasone—Methylprednisolone—multiple sclerosis	0.00138	0.00718	CrCrCtD
Fluocinolone Acetonide—Fluocortolone—Triamcinolone—multiple sclerosis	0.00136	0.0071	CrCrCtD
Fluocinolone Acetonide—Alclometasone—Dexamethasone—multiple sclerosis	0.00136	0.00706	CrCrCtD
Fluocinolone Acetonide—Alclometasone—Betamethasone—multiple sclerosis	0.00136	0.00706	CrCrCtD
Fluocinolone Acetonide—Budesonide—Methylprednisolone—multiple sclerosis	0.00134	0.00699	CrCrCtD
Fluocinolone Acetonide—Alclometasone—Triamcinolone—multiple sclerosis	0.00132	0.0069	CrCrCtD
Fluocinolone Acetonide—Budesonide—Dexamethasone—multiple sclerosis	0.00132	0.00688	CrCrCtD
Fluocinolone Acetonide—Budesonide—Betamethasone—multiple sclerosis	0.00132	0.00688	CrCrCtD
Fluocinolone Acetonide—Amcinonide—Betamethasone—multiple sclerosis	0.00132	0.00688	CrCrCtD
Fluocinolone Acetonide—Amcinonide—Dexamethasone—multiple sclerosis	0.00132	0.00688	CrCrCtD
Fluocinolone Acetonide—Desonide—Methylprednisolone—multiple sclerosis	0.00131	0.00681	CrCrCtD
Fluocinolone Acetonide—Fludrocortisone—Methylprednisolone—multiple sclerosis	0.00131	0.00681	CrCrCtD
Fluocinolone Acetonide—Clobetasol propionate—Methylprednisolone—multiple sclerosis	0.00131	0.00681	CrCrCtD
Fluocinolone Acetonide—Flunisolide—Methylprednisolone—multiple sclerosis	0.00131	0.00681	CrCrCtD
Fluocinolone Acetonide—Diflorasone—Methylprednisolone—multiple sclerosis	0.00131	0.00681	CrCrCtD
Fluocinolone Acetonide—Clocortolone—Prednisolone—multiple sclerosis	0.0013	0.00677	CrCrCtD
Fluocinolone Acetonide—Beclomethasone—Prednisolone—multiple sclerosis	0.0013	0.00677	CrCrCtD
Fluocinolone Acetonide—Fluocortolone—Prednisone—multiple sclerosis	0.00129	0.00674	CrCrCtD
Fluocinolone Acetonide—Amcinonide—Triamcinolone—multiple sclerosis	0.00129	0.00672	CrCrCtD
Fluocinolone Acetonide—Budesonide—Triamcinolone—multiple sclerosis	0.00129	0.00672	CrCrCtD
Fluocinolone Acetonide—Diflorasone—Betamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Diflorasone—Dexamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Desonide—Betamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Clobetasol propionate—Betamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Clobetasol propionate—Dexamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Desonide—Dexamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Fludrocortisone—Betamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Fludrocortisone—Dexamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Flunisolide—Dexamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Flunisolide—Betamethasone—multiple sclerosis	0.00129	0.0067	CrCrCtD
Fluocinolone Acetonide—Paramethasone—Methylprednisolone—multiple sclerosis	0.00127	0.00663	CrCrCtD
Fluocinolone Acetonide—Fluocortolone—Prednisolone—multiple sclerosis	0.00126	0.00658	CrCrCtD
Fluocinolone Acetonide—Alclometasone—Prednisone—multiple sclerosis	0.00126	0.00655	CrCrCtD
Fluocinolone Acetonide—Fludrocortisone—Triamcinolone—multiple sclerosis	0.00126	0.00654	CrCrCtD
Fluocinolone Acetonide—Diflorasone—Triamcinolone—multiple sclerosis	0.00126	0.00654	CrCrCtD
Fluocinolone Acetonide—Flunisolide—Triamcinolone—multiple sclerosis	0.00126	0.00654	CrCrCtD
Fluocinolone Acetonide—Desonide—Triamcinolone—multiple sclerosis	0.00126	0.00654	CrCrCtD
Fluocinolone Acetonide—Clobetasol propionate—Triamcinolone—multiple sclerosis	0.00126	0.00654	CrCrCtD
Fluocinolone Acetonide—Paramethasone—Betamethasone—multiple sclerosis	0.00125	0.00653	CrCrCtD
Fluocinolone Acetonide—Paramethasone—Dexamethasone—multiple sclerosis	0.00125	0.00653	CrCrCtD
Fluocinolone Acetonide—Desoximetasone—Methylprednisolone—multiple sclerosis	0.00124	0.00647	CrCrCtD
Fluocinolone Acetonide—Alclometasone—Prednisolone—multiple sclerosis	0.00123	0.00639	CrCrCtD
Fluocinolone Acetonide—Paramethasone—Triamcinolone—multiple sclerosis	0.00122	0.00638	CrCrCtD
Fluocinolone Acetonide—Amcinonide—Prednisone—multiple sclerosis	0.00122	0.00638	CrCrCtD
Fluocinolone Acetonide—Budesonide—Prednisone—multiple sclerosis	0.00122	0.00638	CrCrCtD
Fluocinolone Acetonide—Desoximetasone—Betamethasone—multiple sclerosis	0.00122	0.00637	CrCrCtD
Fluocinolone Acetonide—Desoximetasone—Dexamethasone—multiple sclerosis	0.00122	0.00637	CrCrCtD
Fluocinolone Acetonide—Mometasone—Methylprednisolone—multiple sclerosis	0.00121	0.00632	CrCrCtD
Fluocinolone Acetonide—Triamcinolone—Methylprednisolone—multiple sclerosis	0.00121	0.00632	CrCrCtD
Fluocinolone Acetonide—Fluorometholone—Methylprednisolone—multiple sclerosis	0.00121	0.00632	CrCrCtD
Fluocinolone Acetonide—Fluprednidene Acetate—Methylprednisolone—multiple sclerosis	0.00121	0.00632	CrCrCtD
Fluocinolone Acetonide—Desoximetasone—Triamcinolone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Amcinonide—Prednisolone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Budesonide—Prednisolone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Fluprednidene Acetate—Dexamethasone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Fluprednidene Acetate—Betamethasone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Fluorometholone—Dexamethasone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Fluorometholone—Betamethasone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Triamcinolone—Betamethasone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Triamcinolone—Dexamethasone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Mometasone—Betamethasone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Mometasone—Dexamethasone—multiple sclerosis	0.00119	0.00622	CrCrCtD
Fluocinolone Acetonide—Flunisolide—Prednisone—multiple sclerosis	0.00119	0.00621	CrCrCtD
Fluocinolone Acetonide—Diflorasone—Prednisone—multiple sclerosis	0.00119	0.00621	CrCrCtD
Fluocinolone Acetonide—Fludrocortisone—Prednisone—multiple sclerosis	0.00119	0.00621	CrCrCtD
Fluocinolone Acetonide—Desonide—Prednisone—multiple sclerosis	0.00119	0.00621	CrCrCtD
Fluocinolone Acetonide—Clobetasol propionate—Prednisone—multiple sclerosis	0.00119	0.00621	CrCrCtD
Fluocinolone Acetonide—Betamethasone—Methylprednisolone—multiple sclerosis	0.00118	0.00618	CrCrCtD
Fluocinolone Acetonide—Rimexolone—Methylprednisolone—multiple sclerosis	0.00118	0.00618	CrCrCtD
Fluocinolone Acetonide—Dexamethasone—Methylprednisolone—multiple sclerosis	0.00118	0.00618	CrCrCtD
Fluocinolone Acetonide—Dexamethasone—Betamethasone—multiple sclerosis	0.00117	0.00608	CrCrCtD
Fluocinolone Acetonide—Rimexolone—Betamethasone—multiple sclerosis	0.00117	0.00608	CrCrCtD
Fluocinolone Acetonide—Rimexolone—Dexamethasone—multiple sclerosis	0.00117	0.00608	CrCrCtD
Fluocinolone Acetonide—Betamethasone—Dexamethasone—multiple sclerosis	0.00117	0.00608	CrCrCtD
Fluocinolone Acetonide—Mometasone—Triamcinolone—multiple sclerosis	0.00117	0.00608	CrCrCtD
Fluocinolone Acetonide—Fluprednidene Acetate—Triamcinolone—multiple sclerosis	0.00117	0.00608	CrCrCtD
Fluocinolone Acetonide—Fluorometholone—Triamcinolone—multiple sclerosis	0.00117	0.00608	CrCrCtD
Fluocinolone Acetonide—Fludrocortisone—Prednisolone—multiple sclerosis	0.00116	0.00606	CrCrCtD
Fluocinolone Acetonide—Flunisolide—Prednisolone—multiple sclerosis	0.00116	0.00606	CrCrCtD
Fluocinolone Acetonide—Clobetasol propionate—Prednisolone—multiple sclerosis	0.00116	0.00606	CrCrCtD
Fluocinolone Acetonide—Desonide—Prednisolone—multiple sclerosis	0.00116	0.00606	CrCrCtD
Fluocinolone Acetonide—Diflorasone—Prednisolone—multiple sclerosis	0.00116	0.00606	CrCrCtD
Fluocinolone Acetonide—Paramethasone—Prednisone—multiple sclerosis	0.00116	0.00605	CrCrCtD
Fluocinolone Acetonide—Rimexolone—Triamcinolone—multiple sclerosis	0.00114	0.00594	CrCrCtD
Fluocinolone Acetonide—Dexamethasone—Triamcinolone—multiple sclerosis	0.00114	0.00594	CrCrCtD
Fluocinolone Acetonide—Betamethasone—Triamcinolone—multiple sclerosis	0.00114	0.00594	CrCrCtD
Fluocinolone Acetonide—Paramethasone—Prednisolone—multiple sclerosis	0.00113	0.00591	CrCrCtD
Fluocinolone Acetonide—Desoximetasone—Prednisone—multiple sclerosis	0.00113	0.00591	CrCrCtD
Fluocinolone Acetonide—Methylprednisolone—Dexamethasone—multiple sclerosis	0.00112	0.00581	CrCrCtD
Fluocinolone Acetonide—Methylprednisolone—Betamethasone—multiple sclerosis	0.00112	0.00581	CrCrCtD
Fluocinolone Acetonide—Prednisolone—Methylprednisolone—multiple sclerosis	0.00111	0.00578	CrCrCtD
Fluocinolone Acetonide—Triamcinolone—Prednisone—multiple sclerosis	0.00111	0.00577	CrCrCtD
Fluocinolone Acetonide—Fluprednidene Acetate—Prednisone—multiple sclerosis	0.00111	0.00577	CrCrCtD
Fluocinolone Acetonide—Mometasone—Prednisone—multiple sclerosis	0.00111	0.00577	CrCrCtD
Fluocinolone Acetonide—Fluorometholone—Prednisone—multiple sclerosis	0.00111	0.00577	CrCrCtD
Fluocinolone Acetonide—Desoximetasone—Prednisolone—multiple sclerosis	0.00111	0.00577	CrCrCtD
Fluocinolone Acetonide—Prednisolone—Betamethasone—multiple sclerosis	0.00109	0.00569	CrCrCtD
Fluocinolone Acetonide—Prednisolone—Dexamethasone—multiple sclerosis	0.00109	0.00569	CrCrCtD
Fluocinolone Acetonide—Methylprednisolone—Triamcinolone—multiple sclerosis	0.00109	0.00568	CrCrCtD
Fluocinolone Acetonide—Betamethasone—Prednisone—multiple sclerosis	0.00108	0.00564	CrCrCtD
Fluocinolone Acetonide—Dexamethasone—Prednisone—multiple sclerosis	0.00108	0.00564	CrCrCtD
Fluocinolone Acetonide—Rimexolone—Prednisone—multiple sclerosis	0.00108	0.00564	CrCrCtD
Fluocinolone Acetonide—Triamcinolone—Prednisolone—multiple sclerosis	0.00108	0.00563	CrCrCtD
Fluocinolone Acetonide—Mometasone—Prednisolone—multiple sclerosis	0.00108	0.00563	CrCrCtD
Fluocinolone Acetonide—Fluorometholone—Prednisolone—multiple sclerosis	0.00108	0.00563	CrCrCtD
Fluocinolone Acetonide—Fluprednidene Acetate—Prednisolone—multiple sclerosis	0.00108	0.00563	CrCrCtD
Fluocinolone Acetonide—Prednisolone—Triamcinolone—multiple sclerosis	0.00107	0.00556	CrCrCtD
Fluocinolone Acetonide—Rimexolone—Prednisolone—multiple sclerosis	0.00106	0.0055	CrCrCtD
Fluocinolone Acetonide—Betamethasone—Prednisolone—multiple sclerosis	0.00106	0.0055	CrCrCtD
Fluocinolone Acetonide—Dexamethasone—Prednisolone—multiple sclerosis	0.00106	0.0055	CrCrCtD
Fluocinolone Acetonide—Methylprednisolone—Prednisone—multiple sclerosis	0.00103	0.00539	CrCrCtD
Fluocinolone Acetonide—Prednisolone—Prednisone—multiple sclerosis	0.00101	0.00528	CrCrCtD
Fluocinolone Acetonide—Methylprednisolone—Prednisolone—multiple sclerosis	0.00101	0.00526	CrCrCtD
Fluocinolone Acetonide—PLA2G4A—Raltitrexed—Methotrexate—multiple sclerosis	0.000409	0.546	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—phospho-PLA2 pathway—MAPK1—multiple sclerosis	0.000207	0.0785	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—HHEX—multiple sclerosis	0.000119	0.0453	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—S1PR1—multiple sclerosis	9.95e-05	0.0377	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	8.87e-05	0.0336	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—CBLB—multiple sclerosis	7.77e-05	0.0294	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—nerve—multiple sclerosis	7.65e-05	0.12	CbGeAlD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	7.23e-05	0.0274	CbGpPWpGaD
Fluocinolone Acetonide—Fluticasone Propionate—PGR—multiple sclerosis	7.18e-05	0.311	CrCbGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—EOMES—multiple sclerosis	6.86e-05	0.026	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—TBX21—multiple sclerosis	6.86e-05	0.026	CbGpPWpGaD
Fluocinolone Acetonide—Betamethasone—PGR—multiple sclerosis	6.58e-05	0.285	CrCbGaD
Fluocinolone Acetonide—Abscess—Dexamethasone—multiple sclerosis	6.56e-05	0.0016	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Cladribine—multiple sclerosis	6.45e-05	0.00158	CcSEcCtD
Fluocinolone Acetonide—Infestation—Cladribine—multiple sclerosis	6.45e-05	0.00158	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Methotrexate—multiple sclerosis	6.35e-05	0.00155	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Fingolimod—multiple sclerosis	6.26e-05	0.00153	CcSEcCtD
Fluocinolone Acetonide—Mania—Prednisone—multiple sclerosis	6.21e-05	0.00152	CcSEcCtD
Fluocinolone Acetonide—Folliculitis—Methotrexate—multiple sclerosis	6.01e-05	0.00147	CcSEcCtD
Fluocinolone Acetonide—Cataract—Triamcinolone—multiple sclerosis	6.01e-05	0.00147	CcSEcCtD
Fluocinolone Acetonide—Glaucoma—Prednisone—multiple sclerosis	6e-05	0.00147	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TBX21—multiple sclerosis	5.91e-05	0.0224	CbGpPWpGaD
Fluocinolone Acetonide—Abscess—Prednisone—multiple sclerosis	5.71e-05	0.0014	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Cladribine—multiple sclerosis	5.69e-05	0.00139	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Triamcinolone—multiple sclerosis	5.65e-05	0.00138	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Betamethasone—multiple sclerosis	5.63e-05	0.00138	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Dexamethasone—multiple sclerosis	5.63e-05	0.00138	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—S1PR1—multiple sclerosis	5.6e-05	0.0212	CbGpPWpGaD
Fluocinolone Acetonide—Wheezing—Triamcinolone—multiple sclerosis	5.55e-05	0.00136	CcSEcCtD
Fluocinolone Acetonide—Triamcinolone—BCHE—multiple sclerosis	5.5e-05	0.238	CrCbGaD
Fluocinolone Acetonide—Cataract—Dexamethasone—multiple sclerosis	5.45e-05	0.00133	CcSEcCtD
Fluocinolone Acetonide—Cataract—Betamethasone—multiple sclerosis	5.45e-05	0.00133	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Cladribine—multiple sclerosis	5.41e-05	0.00132	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—medulla oblongata—multiple sclerosis	5.25e-05	0.0826	CbGeAlD
Fluocinolone Acetonide—Infestation—Azathioprine—multiple sclerosis	5.24e-05	0.00128	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Azathioprine—multiple sclerosis	5.24e-05	0.00128	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Cladribine—multiple sclerosis	5.22e-05	0.00128	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Fingolimod—multiple sclerosis	5.13e-05	0.00126	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Dexamethasone—multiple sclerosis	5.13e-05	0.00125	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Betamethasone—multiple sclerosis	5.13e-05	0.00125	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—PGR—multiple sclerosis	5.12e-05	0.0194	CbGpPWpGaD
Fluocinolone Acetonide—Alopecia—Cladribine—multiple sclerosis	5.12e-05	0.00125	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Cladribine—multiple sclerosis	5.07e-05	0.00124	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Cladribine—multiple sclerosis	5.04e-05	0.00123	CcSEcCtD
Fluocinolone Acetonide—Erythema—Cladribine—multiple sclerosis	5.04e-05	0.00123	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Prednisone—multiple sclerosis	5e-05	0.00122	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Fingolimod—multiple sclerosis	4.96e-05	0.00121	CcSEcCtD
Fluocinolone Acetonide—Back pain—Cladribine—multiple sclerosis	4.87e-05	0.00119	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—midbrain—multiple sclerosis	4.8e-05	0.0755	CbGeAlD
Fluocinolone Acetonide—Dizziness—Fingolimod—multiple sclerosis	4.8e-05	0.00117	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Dexamethasone—multiple sclerosis	4.79e-05	0.00117	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Betamethasone—multiple sclerosis	4.79e-05	0.00117	CcSEcCtD
Fluocinolone Acetonide—Abscess—Methotrexate—multiple sclerosis	4.77e-05	0.00117	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Prednisolone—multiple sclerosis	4.76e-05	0.00117	CcSEcCtD
Fluocinolone Acetonide—Cataract—Prednisone—multiple sclerosis	4.75e-05	0.00116	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—spinal cord—multiple sclerosis	4.68e-05	0.0736	CbGeAlD
Fluocinolone Acetonide—Headache—Fingolimod—multiple sclerosis	4.55e-05	0.00111	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—PABPC1—multiple sclerosis	4.52e-05	0.0171	CbGpPWpGaD
Fluocinolone Acetonide—Upper respiratory tract infection—Mitoxantrone—multiple sclerosis	4.42e-05	0.00108	CcSEcCtD
Fluocinolone Acetonide—Cough—Cladribine—multiple sclerosis	4.4e-05	0.00108	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Cladribine—multiple sclerosis	4.29e-05	0.00105	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Azathioprine—multiple sclerosis	4.24e-05	0.00104	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Betamethasone—multiple sclerosis	4.17e-05	0.00102	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Dexamethasone—multiple sclerosis	4.17e-05	0.00102	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Azathioprine—multiple sclerosis	4.16e-05	0.00102	CcSEcCtD
Fluocinolone Acetonide—Oedema—Cladribine—multiple sclerosis	4.11e-05	0.00101	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Methotrexate—multiple sclerosis	4.1e-05	0.001	CcSEcCtD
Fluocinolone Acetonide—Infection—Cladribine—multiple sclerosis	4.09e-05	0.001	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	4.04e-05	0.0153	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Cladribine—multiple sclerosis	4.03e-05	0.000987	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Mitoxantrone—multiple sclerosis	3.98e-05	0.000973	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Dexamethasone—multiple sclerosis	3.97e-05	0.000972	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Betamethasone—multiple sclerosis	3.97e-05	0.000972	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—nervous system—multiple sclerosis	3.95e-05	0.062	CbGeAlD
Fluocinolone Acetonide—SERPINA6—nervous system—multiple sclerosis	3.93e-05	0.0618	CbGeAlD
Fluocinolone Acetonide—Dexamethasone—PGR—multiple sclerosis	3.83e-05	0.166	CrCbGaD
Fluocinolone Acetonide—Rhinitis—Mitoxantrone—multiple sclerosis	3.82e-05	0.000933	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—central nervous system—multiple sclerosis	3.8e-05	0.0597	CbGeAlD
Fluocinolone Acetonide—SERPINA6—central nervous system—multiple sclerosis	3.78e-05	0.0595	CbGeAlD
Fluocinolone Acetonide—Musculoskeletal discomfort—Cladribine—multiple sclerosis	3.75e-05	0.000917	CcSEcCtD
Fluocinolone Acetonide—SERPINA6—cerebellum—multiple sclerosis	3.7e-05	0.0581	CbGeAlD
Fluocinolone Acetonide—Influenza—Triamcinolone—multiple sclerosis	3.59e-05	0.000877	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—VDR—multiple sclerosis	3.58e-05	0.0135	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Betamethasone—Methylprednisolone—multiple sclerosis	3.57e-05	0.0477	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Dexamethasone—Methylprednisolone—multiple sclerosis	3.57e-05	0.0477	CbGdCrCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Cladribine—multiple sclerosis	3.55e-05	0.000869	CcSEcCtD
Fluocinolone Acetonide—Pain—Cladribine—multiple sclerosis	3.52e-05	0.00086	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Betamethasone—Dexamethasone—multiple sclerosis	3.52e-05	0.047	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Dexamethasone—Betamethasone—multiple sclerosis	3.52e-05	0.047	CbGdCrCtD
Fluocinolone Acetonide—Arthralgia—Azathioprine—multiple sclerosis	3.49e-05	0.000853	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Glycerophospholipid biosynthesis—BCHE—multiple sclerosis	3.44e-05	0.013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Betamethasone—Triamcinolone—multiple sclerosis	3.43e-05	0.0459	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Dexamethasone—Triamcinolone—multiple sclerosis	3.43e-05	0.0459	CbGdCrCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—SELE—multiple sclerosis	3.39e-05	0.0129	CbGpPWpGaD
Fluocinolone Acetonide—Alopecia—Mitoxantrone—multiple sclerosis	3.36e-05	0.000823	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	3.33e-05	0.000816	CcSEcCtD
Fluocinolone Acetonide—Infection—Azathioprine—multiple sclerosis	3.32e-05	0.000813	CcSEcCtD
Fluocinolone Acetonide—Erythema—Mitoxantrone—multiple sclerosis	3.31e-05	0.00081	CcSEcCtD
Fluocinolone Acetonide—NR3C1—brainstem—multiple sclerosis	3.29e-05	0.0517	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Dexamethasone—Prednisone—multiple sclerosis	3.26e-05	0.0436	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Betamethasone—Prednisone—multiple sclerosis	3.26e-05	0.0436	CbGdCrCtD
Fluocinolone Acetonide—Body temperature increased—Cladribine—multiple sclerosis	3.25e-05	0.000795	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Mitoxantrone—multiple sclerosis	3.24e-05	0.000794	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	3.22e-05	0.0122	CbGpPWpGaD
Fluocinolone Acetonide—Back pain—Mitoxantrone—multiple sclerosis	3.2e-05	0.000784	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Methylprednisolone—multiple sclerosis	3.19e-05	0.000781	CcSEcCtD
Fluocinolone Acetonide—Infestation—Methylprednisolone—multiple sclerosis	3.19e-05	0.000781	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Betamethasone—Prednisolone—multiple sclerosis	3.18e-05	0.0425	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Dexamethasone—Prednisolone—multiple sclerosis	3.18e-05	0.0425	CbGdCrCtD
Fluocinolone Acetonide—Vision blurred—Mitoxantrone—multiple sclerosis	3.12e-05	0.000764	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	3.08e-05	0.0117	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	3.05e-05	0.000745	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Cladribine—multiple sclerosis	3.03e-05	0.000741	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—brain—multiple sclerosis	3.02e-05	0.0474	CbGeAlD
Fluocinolone Acetonide—Visual impairment—Prednisolone—multiple sclerosis	3.01e-05	0.000736	CcSEcCtD
Fluocinolone Acetonide—SERPINA6—brain—multiple sclerosis	3e-05	0.0472	CbGeAlD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—C4A—multiple sclerosis	3e-05	0.0114	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Cladribine—multiple sclerosis	2.91e-05	0.000712	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Methotrexate—multiple sclerosis	2.89e-05	0.000708	CcSEcCtD
Fluocinolone Acetonide—Cough—Mitoxantrone—multiple sclerosis	2.89e-05	0.000707	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Azathioprine—multiple sclerosis	2.89e-05	0.000706	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Triamcinolone—multiple sclerosis	2.88e-05	0.000704	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Methylprednisolone—multiple sclerosis	2.87e-05	0.000703	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	2.83e-05	0.0107	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Mitoxantrone—multiple sclerosis	2.82e-05	0.00069	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Methylprednisolone—multiple sclerosis	2.82e-05	0.000689	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Cladribine—multiple sclerosis	2.81e-05	0.000688	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Methylprednisolone—multiple sclerosis	2.76e-05	0.000675	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Cladribine—multiple sclerosis	2.72e-05	0.000665	CcSEcCtD
Fluocinolone Acetonide—Erythema—Prednisolone—multiple sclerosis	2.72e-05	0.000665	CcSEcCtD
Fluocinolone Acetonide—Oedema—Mitoxantrone—multiple sclerosis	2.7e-05	0.000661	CcSEcCtD
Fluocinolone Acetonide—Infection—Mitoxantrone—multiple sclerosis	2.69e-05	0.000657	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Methylprednisolone—multiple sclerosis	2.68e-05	0.000655	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Azathioprine—multiple sclerosis	2.64e-05	0.000647	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Cladribine—multiple sclerosis	2.62e-05	0.00064	CcSEcCtD
Fluocinolone Acetonide—Rash—Cladribine—multiple sclerosis	2.59e-05	0.000634	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Cladribine—multiple sclerosis	2.59e-05	0.000634	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Methylprednisolone—multiple sclerosis	2.58e-05	0.000632	CcSEcCtD
Fluocinolone Acetonide—Headache—Cladribine—multiple sclerosis	2.58e-05	0.00063	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—MERTK—multiple sclerosis	2.57e-05	0.00973	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SELPLG—multiple sclerosis	2.57e-05	0.00973	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CD58—multiple sclerosis	2.57e-05	0.00973	CbGpPWpGaD
Fluocinolone Acetonide—Vision blurred—Prednisolone—multiple sclerosis	2.56e-05	0.000627	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Dexamethasone—multiple sclerosis	2.51e-05	0.000614	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Betamethasone—multiple sclerosis	2.51e-05	0.000614	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Methylprednisolone—multiple sclerosis	2.51e-05	0.000614	CcSEcCtD
Fluocinolone Acetonide—Erythema—Triamcinolone—multiple sclerosis	2.5e-05	0.000611	CcSEcCtD
Fluocinolone Acetonide—Erythema—Methylprednisolone—multiple sclerosis	2.49e-05	0.00061	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Methylprednisolone—multiple sclerosis	2.49e-05	0.00061	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Azathioprine—multiple sclerosis	2.46e-05	0.000603	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	2.46e-05	0.000603	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—IFNB1—multiple sclerosis	2.46e-05	0.00932	CbGpPWpGaD
Fluocinolone Acetonide—Dysgeusia—Triamcinolone—multiple sclerosis	2.45e-05	0.000599	CcSEcCtD
Fluocinolone Acetonide—Nausea—Cladribine—multiple sclerosis	2.44e-05	0.000598	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Prednisolone—multiple sclerosis	2.44e-05	0.000597	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Betamethasone—multiple sclerosis	2.43e-05	0.000596	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Dexamethasone—multiple sclerosis	2.43e-05	0.000596	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK1—multiple sclerosis	2.42e-05	0.00917	CbGpPWpGaD
Fluocinolone Acetonide—Back pain—Triamcinolone—multiple sclerosis	2.42e-05	0.000591	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—BCHE—multiple sclerosis	2.4e-05	0.00908	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Ca-dependent events—MAPK1—multiple sclerosis	2.37e-05	0.009	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ZNF746—multiple sclerosis	2.32e-05	0.00877	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Mitoxantrone—multiple sclerosis	2.31e-05	0.000566	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Betamethasone—multiple sclerosis	2.3e-05	0.000563	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Dexamethasone—multiple sclerosis	2.3e-05	0.000563	CcSEcCtD
Fluocinolone Acetonide—NR3C1—medulla oblongata—multiple sclerosis	2.29e-05	0.036	CbGeAlD
Fluocinolone Acetonide—Diarrhoea—Azathioprine—multiple sclerosis	2.29e-05	0.00056	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	2.28e-05	0.00862	CbGpPWpGaD
Fluocinolone Acetonide—Erythema—Betamethasone—multiple sclerosis	2.27e-05	0.000555	CcSEcCtD
Fluocinolone Acetonide—Erythema—Dexamethasone—multiple sclerosis	2.27e-05	0.000555	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Triamcinolone—multiple sclerosis	2.25e-05	0.000549	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Methylprednisolone—multiple sclerosis	2.24e-05	0.000548	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Prednisone—multiple sclerosis	2.23e-05	0.000545	CcSEcCtD
Fluocinolone Acetonide—Oedema—Prednisolone—multiple sclerosis	2.22e-05	0.000543	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Azathioprine—multiple sclerosis	2.21e-05	0.000541	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Methotrexate—multiple sclerosis	2.2e-05	0.000539	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—MYC—multiple sclerosis	2.2e-05	0.00832	CbGpPWpGaD
Fluocinolone Acetonide—Cough—Triamcinolone—multiple sclerosis	2.18e-05	0.000534	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Mitoxantrone—multiple sclerosis	2.14e-05	0.000523	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL10—multiple sclerosis	2.13e-05	0.00808	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Azathioprine—multiple sclerosis	2.13e-05	0.00052	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Methylprednisolone—multiple sclerosis	2.12e-05	0.000519	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Prednisone—multiple sclerosis	2.12e-05	0.000519	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—STAT3—multiple sclerosis	2.12e-05	0.00802	CbGpPWpGaD
Fluocinolone Acetonide—Infestation—Methotrexate—multiple sclerosis	2.11e-05	0.000517	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Methotrexate—multiple sclerosis	2.11e-05	0.000517	CcSEcCtD
Fluocinolone Acetonide—Rash—Azathioprine—multiple sclerosis	2.11e-05	0.000516	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Azathioprine—multiple sclerosis	2.11e-05	0.000515	CcSEcCtD
Fluocinolone Acetonide—Headache—Azathioprine—multiple sclerosis	2.1e-05	0.000513	CcSEcCtD
Fluocinolone Acetonide—NR3C1—midbrain—multiple sclerosis	2.09e-05	0.0329	CbGeAlD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL4—multiple sclerosis	2.08e-05	0.00786	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—TNF—multiple sclerosis	2.05e-05	0.00777	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—spinal cord—multiple sclerosis	2.04e-05	0.0321	CbGeAlD
Fluocinolone Acetonide—Oedema—Triamcinolone—multiple sclerosis	2.04e-05	0.000499	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Betamethasone—multiple sclerosis	2.04e-05	0.000498	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Dexamethasone—multiple sclerosis	2.04e-05	0.000498	CcSEcCtD
Fluocinolone Acetonide—Infection—Triamcinolone—multiple sclerosis	2.03e-05	0.000496	CcSEcCtD
Fluocinolone Acetonide—Infection—Methylprednisolone—multiple sclerosis	2.02e-05	0.000495	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Prednisone—multiple sclerosis	2e-05	0.00049	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Methylprednisolone—multiple sclerosis	2e-05	0.000488	CcSEcCtD
Fluocinolone Acetonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALB—multiple sclerosis	1.99e-05	0.00755	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Mitoxantrone—multiple sclerosis	1.99e-05	0.000487	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Prednisone—multiple sclerosis	1.99e-05	0.000486	CcSEcCtD
Fluocinolone Acetonide—Nausea—Azathioprine—multiple sclerosis	1.99e-05	0.000486	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Prednisone—multiple sclerosis	1.97e-05	0.000483	CcSEcCtD
Fluocinolone Acetonide—Erythema—Prednisone—multiple sclerosis	1.97e-05	0.000483	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—VDR—multiple sclerosis	1.95e-05	0.00739	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—MAPK1—multiple sclerosis	1.92e-05	0.00729	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—IL10—multiple sclerosis	1.9e-05	0.00719	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Opioid Signalling—POMC—multiple sclerosis	1.9e-05	0.00719	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Prednisolone—multiple sclerosis	1.9e-05	0.000464	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—HLA-A—multiple sclerosis	1.88e-05	0.00712	CbGpPWpGaD
Fluocinolone Acetonide—Vision blurred—Prednisone—multiple sclerosis	1.86e-05	0.000455	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	1.86e-05	0.000455	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	1.85e-05	0.000454	CcSEcCtD
Fluocinolone Acetonide—Oedema—Dexamethasone—multiple sclerosis	1.85e-05	0.000453	CcSEcCtD
Fluocinolone Acetonide—Oedema—Betamethasone—multiple sclerosis	1.85e-05	0.000453	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Mitoxantrone—multiple sclerosis	1.85e-05	0.000453	CcSEcCtD
Fluocinolone Acetonide—Infection—Dexamethasone—multiple sclerosis	1.84e-05	0.00045	CcSEcCtD
Fluocinolone Acetonide—Infection—Betamethasone—multiple sclerosis	1.84e-05	0.00045	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL4—multiple sclerosis	1.83e-05	0.00693	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Methotrexate—multiple sclerosis	1.83e-05	0.000447	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Dexamethasone—multiple sclerosis	1.82e-05	0.000444	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Betamethasone—multiple sclerosis	1.82e-05	0.000444	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Prednisone—multiple sclerosis	1.77e-05	0.000434	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	1.77e-05	0.00672	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	1.77e-05	0.00672	CbGpPWpGaD
Fluocinolone Acetonide—Eye disorder—Methotrexate—multiple sclerosis	1.77e-05	0.000433	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	1.76e-05	0.00668	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PLC beta mediated events—MAPK1—multiple sclerosis	1.75e-05	0.00662	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Triamcinolone—multiple sclerosis	1.74e-05	0.000427	CcSEcCtD
Fluocinolone Acetonide—NR3C1—nervous system—multiple sclerosis	1.72e-05	0.0271	CbGeAlD
Fluocinolone Acetonide—Vomiting—Mitoxantrone—multiple sclerosis	1.72e-05	0.000421	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—G-protein mediated events—MAPK1—multiple sclerosis	1.72e-05	0.0065	CbGpPWpGaD
Fluocinolone Acetonide—Mediastinal disorder—Methotrexate—multiple sclerosis	1.71e-05	0.000418	CcSEcCtD
Fluocinolone Acetonide—Rash—Mitoxantrone—multiple sclerosis	1.7e-05	0.000417	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Mitoxantrone—multiple sclerosis	1.7e-05	0.000417	CcSEcCtD
Fluocinolone Acetonide—Headache—Mitoxantrone—multiple sclerosis	1.69e-05	0.000414	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	1.69e-05	0.000413	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	1.69e-05	0.000413	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Prednisone—multiple sclerosis	1.68e-05	0.000411	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Methotrexate—multiple sclerosis	1.68e-05	0.00041	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Methotrexate—multiple sclerosis	1.66e-05	0.000406	CcSEcCtD
Fluocinolone Acetonide—NR3C1—central nervous system—multiple sclerosis	1.66e-05	0.0261	CbGeAlD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—multiple sclerosis	1.65e-05	0.00627	CbGpPWpGaD
Fluocinolone Acetonide—Malnutrition—Methotrexate—multiple sclerosis	1.65e-05	0.000404	CcSEcCtD
Fluocinolone Acetonide—Erythema—Methotrexate—multiple sclerosis	1.65e-05	0.000404	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Prednisolone—multiple sclerosis	1.63e-05	0.0004	CcSEcCtD
Fluocinolone Acetonide—NR3C1—cerebellum—multiple sclerosis	1.62e-05	0.0255	CbGeAlD
Fluocinolone Acetonide—Dysgeusia—Methotrexate—multiple sclerosis	1.62e-05	0.000395	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Triamcinolone—multiple sclerosis	1.61e-05	0.000394	CcSEcCtD
Fluocinolone Acetonide—Oedema—Prednisone—multiple sclerosis	1.61e-05	0.000394	CcSEcCtD
Fluocinolone Acetonide—Nausea—Mitoxantrone—multiple sclerosis	1.61e-05	0.000393	CcSEcCtD
Fluocinolone Acetonide—Infection—Prednisone—multiple sclerosis	1.6e-05	0.000392	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	1.6e-05	0.000391	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	1.6e-05	0.000391	CcSEcCtD
Fluocinolone Acetonide—Back pain—Methotrexate—multiple sclerosis	1.6e-05	0.000391	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PLEK—multiple sclerosis	1.59e-05	0.00601	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Betamethasone—multiple sclerosis	1.58e-05	0.000387	CcSEcCtD
Fluocinolone Acetonide—Pain—Dexamethasone—multiple sclerosis	1.58e-05	0.000387	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Prednisone—multiple sclerosis	1.58e-05	0.000387	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MMP9—multiple sclerosis	1.56e-05	0.00592	CbGpPWpGaD
Fluocinolone Acetonide—Vision blurred—Methotrexate—multiple sclerosis	1.56e-05	0.000381	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Triamcinolone—multiple sclerosis	1.5e-05	0.000368	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Methylprednisolone—multiple sclerosis	1.5e-05	0.000367	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Methotrexate—multiple sclerosis	1.48e-05	0.000363	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CCL2—multiple sclerosis	1.48e-05	0.00559	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	1.47e-05	0.000359	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Prednisolone—multiple sclerosis	1.47e-05	0.000359	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Betamethasone—multiple sclerosis	1.46e-05	0.000358	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Dexamethasone—multiple sclerosis	1.46e-05	0.000358	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—ICAM1—multiple sclerosis	1.45e-05	0.0055	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Triamcinolone—multiple sclerosis	1.44e-05	0.000353	CcSEcCtD
Fluocinolone Acetonide—Cough—Methotrexate—multiple sclerosis	1.44e-05	0.000352	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Methylprednisolone—multiple sclerosis	1.44e-05	0.000352	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	1.42e-05	0.00536	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Methotrexate—multiple sclerosis	1.41e-05	0.000344	CcSEcCtD
Fluocinolone Acetonide—Rash—Prednisolone—multiple sclerosis	1.4e-05	0.000342	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Prednisolone—multiple sclerosis	1.4e-05	0.000342	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Methylprednisolone—multiple sclerosis	1.39e-05	0.000341	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—STAT3—multiple sclerosis	1.39e-05	0.00527	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Prednisolone—multiple sclerosis	1.39e-05	0.00034	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Triamcinolone—multiple sclerosis	1.35e-05	0.00033	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—MAPK1—multiple sclerosis	1.35e-05	0.0051	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Methylprednisolone—multiple sclerosis	1.35e-05	0.000329	CcSEcCtD
Fluocinolone Acetonide—Infection—Methotrexate—multiple sclerosis	1.34e-05	0.000327	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—POMC—multiple sclerosis	1.33e-05	0.00503	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Methotrexate—multiple sclerosis	1.32e-05	0.000323	CcSEcCtD
Fluocinolone Acetonide—Nausea—Prednisolone—multiple sclerosis	1.32e-05	0.000322	CcSEcCtD
Fluocinolone Acetonide—NR3C1—brain—multiple sclerosis	1.32e-05	0.0207	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Endothelins—MAPK1—multiple sclerosis	1.31e-05	0.00497	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Dexamethasone—multiple sclerosis	1.31e-05	0.00032	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Betamethasone—multiple sclerosis	1.31e-05	0.00032	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Triamcinolone—multiple sclerosis	1.3e-05	0.000317	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Methylprednisolone—multiple sclerosis	1.29e-05	0.000317	CcSEcCtD
Fluocinolone Acetonide—Rash—Triamcinolone—multiple sclerosis	1.29e-05	0.000315	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Triamcinolone—multiple sclerosis	1.28e-05	0.000314	CcSEcCtD
Fluocinolone Acetonide—Rash—Methylprednisolone—multiple sclerosis	1.28e-05	0.000314	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Methylprednisolone—multiple sclerosis	1.28e-05	0.000314	CcSEcCtD
Fluocinolone Acetonide—Headache—Triamcinolone—multiple sclerosis	1.28e-05	0.000313	CcSEcCtD
Fluocinolone Acetonide—Headache—Methylprednisolone—multiple sclerosis	1.27e-05	0.000312	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Prednisone—multiple sclerosis	1.27e-05	0.000312	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Betamethasone—multiple sclerosis	1.27e-05	0.00031	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Dexamethasone—multiple sclerosis	1.27e-05	0.00031	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MAPK1—multiple sclerosis	1.26e-05	0.00479	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IFNG—multiple sclerosis	1.25e-05	0.00475	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	1.23e-05	0.0003	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Betamethasone—multiple sclerosis	1.22e-05	0.000299	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Dexamethasone—multiple sclerosis	1.22e-05	0.000299	CcSEcCtD
Fluocinolone Acetonide—Nausea—Triamcinolone—multiple sclerosis	1.21e-05	0.000296	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	1.21e-05	0.00459	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Methylprednisolone—multiple sclerosis	1.21e-05	0.000296	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Prednisone—multiple sclerosis	1.19e-05	0.000291	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	1.18e-05	0.00446	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Betamethasone—multiple sclerosis	1.18e-05	0.000288	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Dexamethasone—multiple sclerosis	1.18e-05	0.000288	CcSEcCtD
Fluocinolone Acetonide—Rash—Betamethasone—multiple sclerosis	1.17e-05	0.000285	CcSEcCtD
Fluocinolone Acetonide—Rash—Dexamethasone—multiple sclerosis	1.17e-05	0.000285	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—FAS—multiple sclerosis	1.17e-05	0.00442	CbGpPWpGaD
Fluocinolone Acetonide—Dermatitis—Dexamethasone—multiple sclerosis	1.17e-05	0.000285	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Betamethasone—multiple sclerosis	1.17e-05	0.000285	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	1.16e-05	0.000284	CcSEcCtD
Fluocinolone Acetonide—Headache—Betamethasone—multiple sclerosis	1.16e-05	0.000284	CcSEcCtD
Fluocinolone Acetonide—Headache—Dexamethasone—multiple sclerosis	1.16e-05	0.000284	CcSEcCtD
Fluocinolone Acetonide—Pain—Methotrexate—multiple sclerosis	1.15e-05	0.000282	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Prednisone—multiple sclerosis	1.14e-05	0.000279	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—IL10—multiple sclerosis	1.12e-05	0.00426	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—SRM—multiple sclerosis	1.12e-05	0.00424	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SELE—multiple sclerosis	1.12e-05	0.00424	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL2—multiple sclerosis	1.12e-05	0.00422	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ZNF746—multiple sclerosis	1.11e-05	0.00422	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IFNG—multiple sclerosis	1.11e-05	0.00419	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Prednisone—multiple sclerosis	1.1e-05	0.00027	CcSEcCtD
Fluocinolone Acetonide—Nausea—Betamethasone—multiple sclerosis	1.1e-05	0.000269	CcSEcCtD
Fluocinolone Acetonide—Nausea—Dexamethasone—multiple sclerosis	1.1e-05	0.000269	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Opioid Signalling—MAPK1—multiple sclerosis	1.07e-05	0.00406	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	1.07e-05	0.00406	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Prednisone—multiple sclerosis	1.07e-05	0.000261	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Methotrexate—multiple sclerosis	1.06e-05	0.000261	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MMP9—multiple sclerosis	1.06e-05	0.004	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—S1PR1—multiple sclerosis	1.05e-05	0.00398	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Prednisone—multiple sclerosis	1.02e-05	0.000251	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Gene Expression—PTBP1—multiple sclerosis	1.02e-05	0.00386	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Prednisone—multiple sclerosis	1.02e-05	0.000249	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Prednisone—multiple sclerosis	1.02e-05	0.000248	CcSEcCtD
Fluocinolone Acetonide—Headache—Prednisone—multiple sclerosis	1.01e-05	0.000247	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Methotrexate—multiple sclerosis	9.92e-06	0.000243	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—multiple sclerosis	9.83e-06	0.00372	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Prednisone—multiple sclerosis	9.57e-06	0.000234	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Methotrexate—multiple sclerosis	9.53e-06	0.000233	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Methotrexate—multiple sclerosis	9.22e-06	0.000225	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—RGS1—multiple sclerosis	8.93e-06	0.00338	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Methotrexate—multiple sclerosis	8.91e-06	0.000218	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—TGFB1—multiple sclerosis	8.9e-06	0.00337	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MYC—multiple sclerosis	8.72e-06	0.0033	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TGFB1—multiple sclerosis	8.7e-06	0.0033	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Methotrexate—multiple sclerosis	8.56e-06	0.00021	CcSEcCtD
Fluocinolone Acetonide—Rash—Methotrexate—multiple sclerosis	8.49e-06	0.000208	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Methotrexate—multiple sclerosis	8.49e-06	0.000208	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GPR65—multiple sclerosis	8.47e-06	0.00321	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Methotrexate—multiple sclerosis	8.44e-06	0.000206	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—STAT3—multiple sclerosis	8.34e-06	0.00316	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—LINGO1—multiple sclerosis	8.19e-06	0.0031	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—ITGA4—multiple sclerosis	8.09e-06	0.00306	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IFNB1—multiple sclerosis	8.03e-06	0.00304	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Methotrexate—multiple sclerosis	8e-06	0.000196	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP24A1—multiple sclerosis	7.9e-06	0.00299	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP27B1—multiple sclerosis	7.9e-06	0.00299	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	7.76e-06	0.00294	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MYC—multiple sclerosis	7.75e-06	0.00294	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	7.75e-06	0.00293	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CXCL13—multiple sclerosis	7.75e-06	0.00293	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCR1—multiple sclerosis	7.75e-06	0.00293	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—U2AF2—multiple sclerosis	7.73e-06	0.00293	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—HNRNPA1—multiple sclerosis	7.73e-06	0.00293	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	7.72e-06	0.00292	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MAPK1—multiple sclerosis	7.58e-06	0.00287	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK1—multiple sclerosis	7.52e-06	0.00285	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GPC5—multiple sclerosis	7.22e-06	0.00274	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TAGAP—multiple sclerosis	7.1e-06	0.00269	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—PGR—multiple sclerosis	6.99e-06	0.00265	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL6—multiple sclerosis	6.55e-06	0.00248	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	6.28e-06	0.00238	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—S1PR1—multiple sclerosis	6.21e-06	0.00235	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ZFP36L1—multiple sclerosis	6.11e-06	0.00231	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GPC5—multiple sclerosis	6.04e-06	0.00229	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—RRM1—multiple sclerosis	5.98e-06	0.00227	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	5.9e-06	0.00223	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—multiple sclerosis	5.78e-06	0.00219	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—STAT3—multiple sclerosis	5.72e-06	0.00217	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IL2RA—multiple sclerosis	5.52e-06	0.00209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	5.52e-06	0.00209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCL3—multiple sclerosis	5.52e-06	0.00209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	5.51e-06	0.00209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	5.4e-06	0.00205	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PTGER4—multiple sclerosis	5.31e-06	0.00201	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TGFB1—multiple sclerosis	5.3e-06	0.00201	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—RGS1—multiple sclerosis	5.28e-06	0.002	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	5.14e-06	0.00195	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CXCR3—multiple sclerosis	5.13e-06	0.00194	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GPR65—multiple sclerosis	5e-06	0.0019	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCR2—multiple sclerosis	4.99e-06	0.00189	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TNF—multiple sclerosis	4.95e-06	0.00188	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	4.9e-06	0.00186	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—VDR—multiple sclerosis	4.88e-06	0.00185	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	4.81e-06	0.00182	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PABPC1—multiple sclerosis	4.74e-06	0.00179	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.64e-06	0.00176	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CNR1—multiple sclerosis	4.61e-06	0.00175	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCR1—multiple sclerosis	4.58e-06	0.00173	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CXCL13—multiple sclerosis	4.58e-06	0.00173	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—TNF—multiple sclerosis	4.28e-06	0.00162	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—RPL5—multiple sclerosis	4.27e-06	0.00162	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CXCL10—multiple sclerosis	4.15e-06	0.00157	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IL6—multiple sclerosis	3.99e-06	0.00151	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—ALB—multiple sclerosis	3.99e-06	0.00151	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.99e-06	0.00151	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.64e-06	0.00138	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCL5—multiple sclerosis	3.57e-06	0.00135	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—IL6—multiple sclerosis	3.45e-06	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—BCHE—multiple sclerosis	3.44e-06	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PGR—multiple sclerosis	3.36e-06	0.00127	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCL3—multiple sclerosis	3.26e-06	0.00124	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IL2—multiple sclerosis	3.24e-06	0.00123	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCR5—multiple sclerosis	3.22e-06	0.00122	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL2RA—multiple sclerosis	3.17e-06	0.0012	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTGER4—multiple sclerosis	3.14e-06	0.00119	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PGR—multiple sclerosis	3.09e-06	0.00117	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CXCR3—multiple sclerosis	3.03e-06	0.00115	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CD28—multiple sclerosis	3e-06	0.00114	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCR2—multiple sclerosis	2.95e-06	0.00112	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CNR1—multiple sclerosis	2.72e-06	0.00103	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TGFB1—multiple sclerosis	2.53e-06	0.000957	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—POMC—multiple sclerosis	2.51e-06	0.000952	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—MAPK1—multiple sclerosis	2.48e-06	0.000938	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CCL2—multiple sclerosis	2.46e-06	0.000932	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CXCL10—multiple sclerosis	2.45e-06	0.000928	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—VDR—multiple sclerosis	2.35e-06	0.00089	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—TYK2—multiple sclerosis	2.23e-06	0.000846	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CD86—multiple sclerosis	2.14e-06	0.000812	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCL5—multiple sclerosis	2.11e-06	0.000799	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—APOE—multiple sclerosis	2.07e-06	0.000783	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SPP1—multiple sclerosis	1.95e-06	0.00074	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MYC—multiple sclerosis	1.94e-06	0.000735	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCR5—multiple sclerosis	1.9e-06	0.00072	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL2RA—multiple sclerosis	1.87e-06	0.000709	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL2—multiple sclerosis	1.86e-06	0.000704	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—POMC—multiple sclerosis	1.78e-06	0.000673	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—APOE—multiple sclerosis	1.73e-06	0.000655	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ALB—multiple sclerosis	1.62e-06	0.000613	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CD80—multiple sclerosis	1.56e-06	0.000592	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—POMC—multiple sclerosis	1.49e-06	0.000563	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCL2—multiple sclerosis	1.45e-06	0.00055	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—MAPK1—multiple sclerosis	1.42e-06	0.000539	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TYK2—multiple sclerosis	1.32e-06	0.0005	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL2—multiple sclerosis	1.1e-06	0.000416	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL6—multiple sclerosis	1.09e-06	0.000414	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MMP9—multiple sclerosis	1.04e-06	0.000394	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MYC—multiple sclerosis	9.34e-07	0.000354	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—STAT3—multiple sclerosis	9.24e-07	0.00035	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MYC—multiple sclerosis	8.58e-07	0.000325	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TGFB1—multiple sclerosis	8.56e-07	0.000324	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MAPK1—multiple sclerosis	8.4e-07	0.000318	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL6—multiple sclerosis	6.45e-07	0.000244	CbGpPWpGaD
